These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 20222313)

  • 1. [Monoclonal antibody therapy for non-Hodgkin's lymphoma].
    Paul F; Rossi JF; Cartron G
    Rev Prat; 2010 Jan; 60(1):59-63. PubMed ID: 20222313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
    Fanale MA; Younes A
    Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus R
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab immunotherapy for non-Hodgkin's lymphoma.
    White CA
    Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monoclonal antibodies in hematology in 2009].
    Bonnet C; Beguin Y; De Prijck B; Witvrouw N; Hustinx R; Fillet G
    Rev Med Liege; 2009; 64(5-6):268-73. PubMed ID: 19642457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Witzig TE
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):74-8. PubMed ID: 11226003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
    Molina A
    Annu Rev Med; 2008; 59():237-50. PubMed ID: 18186705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
    King KM; Younes A
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab: ongoing and future clinical development.
    Grillo-López AJ; Hedrick E; Rashford M; Benyunes M
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):105-12. PubMed ID: 11842397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma.
    Traullé C; Coiffier BB
    Future Oncol; 2005 Jun; 1(3):297-306. PubMed ID: 16556002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituxan immunotherapy and zevalin radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    White CA
    Curr Pharm Biotechnol; 2003 Aug; 4(4):221-38. PubMed ID: 14529425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
    Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA
    J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel antibodies in the treatment of non-Hodgkin's lymphoma.
    Bhat SA; Czuczman MS
    Neth J Med; 2009 Sep; 67(8):311-21. PubMed ID: 19767657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Proteins in haematology].
    Clarenbach RE; Mey U
    Ther Umsch; 2011 Nov; 68(11):610-7. PubMed ID: 22045523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab (Rituxan/MabThera): the first decade (1993-2003).
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):767-79. PubMed ID: 14686699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.
    Hainsworth JD
    Semin Oncol; 2003 Feb; 30(1 Suppl 2):9-15. PubMed ID: 12652459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma.
    Wiseman GA; Leigh B; Erwin WD; Lamonica D; Kornmehl E; Spies SM; Silverman DH; Witzig TE; Sparks RB; White CA
    Cancer; 2002 Feb; 94(4 Suppl):1349-57. PubMed ID: 11877765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.